Compare FEIM & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | BCYC |
|---|---|---|
| Founded | 1961 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 439.6M | 360.7M |
| IPO Year | 1994 | 2019 |
| Metric | FEIM | BCYC |
|---|---|---|
| Price | $56.58 | $5.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $51.50 | $13.90 |
| AVG Volume (30 Days) | 201.8K | ★ 574.3K |
| Earning Date | 03-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.95 | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $69,811,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.73 | N/A |
| P/E Ratio | $142.00 | ★ N/A |
| Revenue Growth | ★ 26.30 | N/A |
| 52 Week Low | $16.50 | $4.24 |
| 52 Week High | $61.47 | $9.55 |
| Indicator | FEIM | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 60.34 | 53.49 |
| Support Level | $49.46 | $5.03 |
| Resistance Level | $59.68 | $5.90 |
| Average True Range (ATR) | 4.35 | 0.26 |
| MACD | 1.39 | 0.09 |
| Stochastic Oscillator | 87.74 | 75.68 |
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.